Why LENZ Therapeutics, Inc.’s (LENZ) Stock Is Up 7.36%
As of Wednesday, September 02, LENZ Therapeutics, Inc.’s LENZ share price has surged by 7.36%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
LENZ Therapeutics, Inc. operates as a commercial pharmaceutical company that focuses on the development and commercialization of therapies to improve vision in the United States. Its product candidates include VIZZ and LNZ101 for the treatment of presbyopia in adults. LENZ Therapeutics, Inc. was formerly known as Presbyopia Therapies, Inc. and changed its name to LENZ Therapeutics, Inc. in June 2021. The company was founded in 2013 and is headquartered in Solana Beach, California.
Commentary & Analysis
Why LENZ Therapeutics, Inc.’s (LENZ) Stock Is Up 5.58%
As of Friday, August 21, LENZ Therapeutics, Inc.’s LENZ share price has surged by 5.58%, which has investors questioning if this is right time to sell.Cynthia McLaughlin
Why LENZ Therapeutics, Inc.’s (LENZ) Stock Is Down 5.16%
As of Thursday, August 13, LENZ Therapeutics, Inc.’s LENZ share price has dipped by 5.16%, which has investors questioning if this is right time to buy.Cynthia McLaughlin
Why LENZ Therapeutics, Inc.’s (LENZ) Stock Is Up 9.40%
As of Wednesday, August 12, LENZ Therapeutics, Inc.’s LENZ share price has surged by 9.40%, which has investors questioning if this is right time to sell.Rosalio Madrigal
What You Need to Know About LENZ Therapeutics, Inc.'s Q3 Earnings
LENZ Therapeutics, Inc.'s fiscal Q3 earnings report was released on Tuesday, August 11. Let's dive in to see if (LENZ) missed or beat analyst's expectations.Jenna Brashear
Financial Summary
| Share Statistics | LENZ | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $182.2 | $674.0 | 26% |
|
| Shares Out (Mil) | 31.4 | 43.9 | 38% |
|
| Institutional Ownership | 96.5% | 84.7% | 70% |
|
| Float (Mil) | 18.4 | 47.3 | 28% |
|
| Beta | 1.63 | 0.71 | 86% |
|
| Avg Daily Volume (000s) | 606 | 293 | 63% |
|
| Price Change (52-week) |
(85.2%) | 68.8% | 5% |
|
| Growth | LENZ | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 6.8% | na |
|
| Net Income (5yr) | na | (1.5%) | na |
|
| EPS (5yr) | na | 14.9% | na |
|
| Dividends (5yr) | na | 0.0% | 0% |
|
| Cash Flow (5yr) | na | (15.1%) | na |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 6 | 6 | 6 | |
| Current EPS | ($0.977) | ($4.245) | ($3.075) | |
| Month Ago EPS | ($0.942) | ($4.564) | ($3.507) | |
| # Rev Up | 0 | 0 | 1 | |
| # Rev Down | 1 | 1 | 1 | |
| Three Months Ago EPS | ($1.019) | ($4.561) | ($3.468) | |
| Year/Year Chg | (3.9%) | 48.9% | (54.3%) | |
| Financials | LENZ | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $22 | $317 | 13% |
|
| Net Income (TTM) (Mil) | ($126) | ($11) | 9% |
|
| EPS (TTM) | ($4.119) | ($0.700) | 9% |
|
| Operating Cash Flow (TTM) (Mil) | ($114) | ($7) | 6% |
|
| Net Cash Flow (TTM) (Mil) | ($14) | $4 | 28% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $6 | 10% |
|
| Enterprise Value (Q1) (Mil) | ($61) | $575 | 1% |
|
| Valuation | LENZ | Industry Median |
Percentile (All Stocks) |
|
| P/B | 0.83 | 2.80 | 16% |
|
| P/E | na | 17.4 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 1.1 | na |
|
| Ratios | LENZ | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 91.7% | 67.5% | 94% |
|
| Net Margin | (586.7%) | (1.4%) | 1% |
|
| ROA | (55.5%) | (24.6%) | 11% |
|
| ROE | (59.2%) | (21.4%) | 14% |
|
| Liabilities to Assets | 7.3% | 32.2% | 4% |
|
| F-Score | 2 | 3 | 7% |
|
LENZ Therapeutics, Inc. did not pass any screens on 9/2/2026.
